ABL1 Kinase Domain Mutation Analysis 
Methodology Molecular 
Test Name ABL1 Kinase Domain Mutation Analysis 
Test Description RT-PCR and sequencing of the BCR-ABL1 fusion transcript for qualitative detection of mutations associated with resistance to imatinib and other tyrosine kinase inhibitors.  Analysis includes detection of the common T315I mutation.  
Clinical Significance Testing is recommended in CML with poor initial response to imatinib,  relapse, or progression to accelerated/blast phase.  Presence and identity of mutation may direct management to alternative drugs or stem cell transplant.   
Specimen Requirements
  • Peripheral blood: 5 mL in EDTA tube.
  • Bone marrow: 2 mL in EDTA tube.
 
Storage and Transportation Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <72 hours old preferred. 
Turn Around Time (TAT) 10 days  
CPT Codes 81401